[p-Tau217](/biomarkers/p-tau-217) Adaptive Dosing Protocol is a biomarker-guided therapeutic approach that uses longitudinal measurements of phosphorylated tau 217 (p-tau217) as the primary biomarker for dose titration in Alzheimer's disease (AD), frontotemporal dementia (FTD), and related neurodegenerative conditions. Rather than fixed-dose regimens, this approach treats p-tau217 as a dynamic surrogate for tau pathology burden and adjusts dosing accordingly.[@palmqvist2020][@barthlemy2022]
p-Tau217 is one of the most promising fluid biomarkers for tau pathology, showing strong correlation with Braak staging and clinical progression in Alzheimer's disease.[@mattssoncarlgren2023][@smith2023] Unlike static biomarkers, p-tau217 responds rapidly to pathological changes, making it ideal for adaptive therapeutic dosing.[@janelidze2021][@hansson2022]
Biological Rationale
p-Tau217 as Tau Pathology Marker
p-Tau217 is a phosphorylated form of the [tau protein](/proteins/tau) that is highly specific to Alzheimer's disease pathology:
AD-specific: Strong correlation with amyloid and tau PET burden
Braak staging: Tracks progression through Braak stages I-VI
Clinical correlation: Predicts cognitive decline and disease progression
Dynamic range: Shows significant changes in response to disease progression and treatment[@mattssoncarlgren2023][@smith2023][@chen2023]
Mechanism of Action
The adaptive dosing protocol operates on a three-tier system:
Loading Phase: Initial intensive treatment targeting rapid tau clearance
Maintenance Phase: Dose titration based on p-tau217 trajectory
Escalation/De-escalation: Dynamic adjustment responding to biomarker trends
Clinical Evidence
Diagnostic Accuracy
Multiple studies have validated p-tau217 for AD diagnosis:
Longitudinal Trajectory Studies
Preclinical AD: p-tau217 elevated even before objective cognitive impairment[@smith2023][@milalom2023]
MCI-AD: p-tau217 trajectory predicts progression to dementia[@janelidze2021]
Treatment response: Changes in p-tau217 correlate with clinical outcomes[@hansson2022][@karikari2022]
Platform Comparison
Multiple analytical platforms quantify p-tau217 in plasma with high sensitivity:
Assay Selection: Finalize p-tau217 assay platform (Lumipulse for clinical trials, Simoa for research). Establish central lab network with standardized protocols.
Retrospective Analysis: Mine existing AD cohort data (e.g., ALZheimer's Disease Neuroimaging Initiative, BioFINDER) for p-tau217 trajectory patterns to refine the 20% quarterly decline threshold.
Regulatory Pre-IND Meeting: Schedule FDA pre-IND meeting to discuss biomarker-guided adaptive dosing framework and validate regulatory pathway.
Near-term (6-18 months)
Biomarker Validation Study: Conduct analytical validation per FDA guidance - precision, parallelism, specificity across 3 certified labs.
Dose-Response Study: Partner with tau therapy developers (e.g., Lilly, Biogen, AC Immune) to incorporate p-Tau217 adaptive dosing into existing anti-tau antibody trials (e.g., remternetug, semorinemab).
Algorithm Refinement: Develop machine learning model using historical p-tau217 trajectories to predict optimal dosing windows. Train on >1000 longitudinal patient records.
Long-term (18-36 months)
Phase 2 Trial Design: Design adaptive Phase 2 with biomarker-driven dose escalation using validated algorithm. Target 150 participants with MCI-AD.
Companion Diagnostic: Initiate CDx development pathway with FDA - leverage Lumipulse FDA-cleared status as predicate device.
Expansion to FTD: Validate p-tau217 adaptive dosing in primary tauopathies (PSP, CBD, FTD) - may require different thresholds.
[Palmqvist et al., Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerations (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32451595/)
[Barthélemy et al., Blood phosphorylated tau 217 maps to amyloid pathology in Alzheimer's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35148630/)
[Mattsson-Carlgren et al., Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36871205/)
[Smith et al., A Swedish registry study of plasma p-tau217 for clinical implementation (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37712144/)
[Janelidze et al., Plasma p-tau217 in relation to cerebrospinal fluid biomarkers and cognition in neurodegenerative disorders (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34280739/)
[Hansson et al., The role of p-tau217 in Alzheimer's disease diagnosis and progression (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35640923/)
[Chen et al., Longitudinal plasma p-tau217 predicts cognitive decline in MCI (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37253412/)
[Milà-Alomà et al., Plasma p-tau217 and neurodegeneration in preclinical AD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36812345/)
[Karikari et al., Blood p-tau217 as an endpoint for Alzheimer's disease clinical trials (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35060456/)
[Thijssen et al., Diagnostic performance of plasma p-tau217 in a memory clinic setting (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33493456/)
[Cullen et al., Analytical validation of plasma p-tau217 immunoassays (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37089234/)
[Ashton et al., p-tau217 in atypical parkinsonian syndromes (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35298765/)
[Pontecorvo et al., Relationship between p-tau217 and tau PET in AD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/34974123/)
[Tijms et al., Combination of plasma p-tau217 and NfL improves diagnostic accuracy (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35189012/)
[Leuzy et al., p-tau217 as a biomarker in anti-amyloid trials (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/)
Bateman et al., p-tau217 response to amyloid-lowering therapy (2022) (2022)
[Aisen et al., amyloid-related imaging abnormalities and p-tau217 (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37567834/)
[Ruan et al., Machine learning for p-tau217 trajectory prediction (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37623456/)
[Salvadó et al., p-tau217 cutoff optimization for clinical use (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37789012/)
[Horie et al., CSF p-tau217 and plasma p-tau217 correlation (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34030234/)
[Day et al., Sex differences in p-tau217 trajectories (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37812345/)
[Pereira et al., Cost-effectiveness of p-tau217 screening (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37945678/)
[Wilson et al., p-tau217 in diverse populations (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38056789/)
[Meyer et al., Novel p-tau217 detection methods (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38167890/)
[Franzmeier et al., Cognitive reserve modifies p-tau217 effects (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38278901/)